Furoscix ReadyFlow adoption trajectory and Q4 revenue commentary (management expects Furoscix Q4 revenue to exceed H1 2026 total) are the key near-term catalysts. Monitor the Q4 2026 earnings call for Furoscix revenue, Afrezza pediatric prescription trends, and any update on the inhaled GLP-1 program with Rose Pharma.
Drugs in focus
MNKD drug pipeline →nintedanib DPI
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2 (enrolling)
- Time to market
- At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials and subsequent regulatory filings
- Next catalyst
- None dated
What to watchWatch for Phase 2 INFLO-2 enrollment completion updates and eventual topline efficacy data (likely 12-18 months out). For MNKD overall, the approved Afrezza and Furoscix franchises are nearer-term value drivers; nintedanib DPI is a pipeline optionality play. MannKind's analyst consensus is Strong Buy (12 Buy/Strong Buy vs 2 Hold) with a mean price target of $7.97 (84% upside from ~$4.07), but the stock also shows elevated short-volume ratios, indicating debate.
Price Chart
Executive Summary
MannKind reported Q3 2026 total revenue of $101.9M (+24% YoY), driven by Furoscix ($22.4M, up from zero) and royalties (+12%). GAAP net loss was $23.2M ($-0.07/share) vs. net income of $8.0M a year ago, as SG&A more than doubled to $61.4M to support two commercial launches. The Furoscix ReadyFlow autoinjector was approved and shipments began in mid-September, with rapid adoption reaching ~75% of weekly shipments by late October. No consensus-based EPS or revenue surprise can be computed because the Street consensus of $-0.08 EPS and $108.5M revenue is for a different fiscal quarter (Sep 2026) than the one reported (three months ended Sep 30, 2026).
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $101.9M, +24% vs. Q3 2025
- Commercial product revenue $45.0M, +102% vs. Q3 2025
- Furoscix net revenue $22.4M (vs. zero in Q3 2025); ReadyFlow approved and launched mid-September
- Afrezza net sales $19.3M, +5% YoY; pediatric launch drove ~80% increase in new-to-brand prescriptions QoQ
- Royalties $37.5M, +12% YoY, driven by United Therapeutics' Tyvaso DPI sales
- GAAP net loss $23.2M ($-0.07/share) vs. net income $8.0M ($0.03/share) in Q3 2025
- Non-GAAP adjusted net loss $3.6M ($-0.01/share) vs. non-GAAP net income $22.4M ($0.07/share) in Q3 2025
- SG&A $61.4M, +111% YoY, due to launch activities for Furoscix ReadyFlow and Afrezza pediatric
- Cash, cash equivalents and investments $96.6M at Sep 30, 2026
- Closed $50M private placement on July 24, 2026 to fund $45M CVR payment from Furoscix ReadyFlow approval
- Entered licensing agreement with Rose Pharma for inhaled GLP-1 for weight management
- Anticipates $15M in milestone payments from United Therapeutics for ralinepag DPI in 2027
Financial Impact
Revenue growth of $19.7M YoY (+24%), but GAAP net loss widened by $31.2M vs. prior year due to launch-related SG&A spending
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Afrezza | $19.3M | +5.0% |
| Furoscix | $22.4M | Not reported |
| V-Go | $3.3M | -14.0% |
| Collaborations and services | $19.4M | -27.0% |
| Royalties | $37.5M | +12.0% |
Risk Factors
- SG&A more than doubled to $61.4M, raising questions about path to profitability
- Cash burn continues; cash and investments declined from $134M at Mar 31, 2026 to $96.6M at Sep 30, 2026
- Furoscix gross margin is lower than Afrezza, pressuring overall margins
- Collaborations and services revenue declined 27% YoY due to lower product sold to United Therapeutics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-449743 |
| Document: mnkd-20261105.htm | 0001193125-26-449743 |
| Document: 0001193125-26-449743-index-headers.html | 0001193125-26-449743 |
| Document: 0001193125-26-449743-index.html | 0001193125-26-449743 |
| Document: 0001193125-26-449743.txt | 0001193125-26-449743 |
| 8-K Data (Synthetic) | 0001193125-26-449743 |
Track record
17 reports on MNKD
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers